Exor N.V.’s Neumora Therapeutics NMRA Stock Holding History

Exor N.V.’s Portfolio NMRA Stock Details NMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.51M	Hold	4,215,662	–	–	0.01%	7
2026 Q2	$7.17M	Hold	4,215,662	–	–	0.03%	7
2026 Q1	$8.22M	Hold	4,215,662	–	–	0.03%	7
2025 Q4	$7.55M	Hold	4,215,662	–	–	0.03%	7
2025 Q3	$7.67M	Hold	4,215,662	–	–	0.02%	7
2025 Q2	$3.09M	Hold	4,215,662	–	–	0.01%	7
2025 Q1	$4.22M	Hold	4,215,662	–	–	0.01%	7
2024 Q4	$44.7M	Hold	4,215,662	–	–	0.13%	6
2024 Q3	$55.7M	Hold	4,215,662	–	–	0.15%	6
2024 Q2	$41.4M	Hold	4,215,662	–	–	0.12%	7
2024 Q1	$58M	Hold	4,215,662	–	–	0.14%	7
2023 Q4	$71.9M	Hold	4,215,662	–	–	0.21%	7
2023 Q3	$59.5M	Buy	+4,215,662	New	+$52.7M	0.2%	7

Other funds holding NMRA

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.16B AUM 11.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $714M AUM 64.22% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.6B AUM 33.98% 1-Year Est. Return

Exor N.V.'s NMRA Position: Q3 2026 in Review

Exor N.V. held its Neumora Therapeutics (NMRA) position steady in Q3 2026 at 4,215,662 shares worth $2.51M. The position accounts for 0.01% of the portfolio, ranked #7.

Exor N.V. first reported a position in NMRA in Q3 2023 and has held it in 13 quarters since. The position peaked at $71.9M in Q4 2023. 68 funds tracked by Wall St. Rank hold NMRA as of Q3 2026.

Exor N.V. held 4,215,662 shares of Neumora Therapeutics worth $2.51M as of Q3 2026.
Exor N.V. left its Neumora Therapeutics share count unchanged in Q3 2026.
Neumora Therapeutics made up 0.01% of Exor N.V.'s portfolio in Q3 2026, its #7 holding.
Exor N.V. first reported a position in Neumora Therapeutics in Q3 2023 and has held it in 13 quarters since.
Exor N.V.'s Neumora Therapeutics position peaked at $71.9M in Q4 2023.
68 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q3 2026.

Based on Exor N.V.'s 13F filing for Q3 2026, filed 13 Nov 2026.